

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**QingSong Health Corporation**

**轻松健康集团**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2661)**

**CHANGE OF JOINT COMPANY SECRETARY AND PROCESS AGENT  
AND  
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17  
OF THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of QingSong Health Corporation (the “**Company**”) hereby announces that Mr. CHOW Shing Lung (“**Mr. Chow**”) has resigned as (i) a joint company secretary of the Company (“**Joint Company Secretary**”); and (ii) the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from March 23, 2026.

Mr. Chow confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to his resignation.

The Board further announces that, following Mr. Chow’s resignation as a Joint Company Secretary and the Process Agent, Ms. CHAN Ching Nga (“**Ms. Chan**”) has been appointed as a Joint Company Secretary and the Process Agent with effect from March 23, 2026. Mr. YANG Lei (“**Mr. Yang**”) will continue to act as the other Joint Company Secretary.

The biographical details of Ms. Chan and Mr. Yang are as follows:

### **Ms. Chan**

Ms. Chan has over 20 years of experience in company secretarial and corporate governance fields and is currently a Senior Manager, Entity Solutions at Computershare Hong Kong Investor Services Limited. She obtained a master's degree in corporate governance from The Hong Kong Polytechnic University in October 2012. Ms. Chan is an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

### **Mr. Yang**

Mr. Yang was appointed as a Joint Company Secretary with effect from December 23, 2025. He has been the strategy and investor relations specialist of the Company and its subsidiaries (collectively, the “**Group**”) since April 2023, and is primarily responsible for corporate governance and secretarial affairs of the Board and investors.

Prior to joining our Group, Mr. Yang worked at Deloitte Touche Tohmatsu Certified Public Accountants LLP Beijing Branch (德勤華永會計師事務所(特殊普通合夥)北京分所) from September 2011 to April 2014, with his last position being a senior auditor. He also worked at Tyco Fire & Security (Beijing) Co. Ltd. (泰科(北京)安裝工程有限公司) (a company listed on New York Stock Exchange, stock code: TYC) from May 2014 to September 2017, with his last position being an FP&A Analyst. He further served as the financial manager of Beijing Qingsongchou Network Technology Co., Ltd. (北京輕鬆籌網絡科技有限公司) from October 2018 to September 2019, and the financial manager and researcher of Guangdao Asset Management Co. Ltd. (光道資產管理有限公司) from September 2019 to April 2023.

## **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the waiver (the “**Existing Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) in relation to the eligibility of Mr. Yang to act as a Joint Company Secretary for a three-year period starting from the date of listing of the Company's shares on the Stock Exchange (i.e. December 23, 2025) (the “**Original Waiver Period**”), on the condition that Mr. Yang must be assisted by Mr. Chow as a Joint Company Secretary during the Original Waiver Period to enable Mr. Yang to acquire relevant experience (as defined in Note 2 to Rule 3.28 of the Listing Rules), in order to discharge his duties under the position of a Joint Company Secretary. Such waiver will be revoked upon Mr. Chow's resignation on March 23, 2026. Relevant details of the Existing Waiver were disclosed in the prospectus of the Company dated December 15, 2025.

In view of Mr. Chow's resignation, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a new waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Mr. Yang to act as a Joint Company Secretary (the "**New Waiver**") from March 23, 2026 (i.e. from the effective date of Ms. Chan's appointment) to December 22, 2028 (i.e. the remaining period of the Existing Waiver) (the "**Remaining Waiver Period**"). The New Waiver has been granted on the following conditions:

- (i) Mr. Yang must be assisted by Ms. Chan during the Remaining Waiver Period; and
- (ii) The New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Mr. Yang, having had the benefit of Mr. Chow and Ms. Chan's assistance for approximately three years, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chow for his valuable contribution and services to the Company during his tenure of office, and welcome Ms. Chan for her new appointment as a Joint Company Secretary and the Process Agent.

By Order of the Board  
**QingSong Health Corporation**  
轻松健康集团  
**YANG Yin**

*Chairlady of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, March 23, 2026

*As at the date of this announcement, the Board comprises (i) Ms. YANG Yin and Ms. WANG Jing as executive Directors; (ii) Mr. ZHAO Yuping, Mr. ZHENG Kaihuan and Mr. WU Bin as non-executive Directors; and (iii) Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming and Mr. BAI Kun as independent non-executive Directors.*